Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $2.94M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 100,061 shares of Alamar Biosciences, Inc. at $29.34 to $30.63 a share (average $29.38) in 7 transactions, worth $2.94M in total on Nov 11, 2026. Shares held after the trade: 1,632,188 (-0.0%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $3.33M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 111,313 shares of Alamar Biosciences, Inc. at $29.89 a share, worth $3.33M in total on Nov 3, 2026. Shares held after the trade: 1,650,354 (-1.2%).
Alamar Biosciences reported total revenue of $89.0 million for the nine months ended September 30, 2026, representing significant growth compared to $49.2 million in the prior year period. Despite this growth, the company incurred a net loss of $47.9 million for the period as it continues to invest heavily in research, development, and commercial expansion.
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $5.66M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 187,040 shares of Alamar Biosciences, Inc. at $29.84 to $33.31 a share (average $30.25) in 17 transactions, worth $5.66M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 1,670,586 (-0.5%).
Alamar Biosciences reported Q3 2026 revenue of $33.5 million, a 68% year-over-year increase driven by strong demand for its NULISA platform and consumables. The company raised its full-year 2026 revenue guidance to a range of $121-$123 million and announced the retirement of President Tod White effective December 31, 2026.
Term
Q3 2026
“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time. Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
“Tod has been an outstanding partner and leader during a pivotal period for Alamar. He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase. On behalf of our board and the entire team, I thank Tod for his many contributions and wish him the very best in his retirement.”
Yuling Luo, Ph.D., Founder, Chief Executive Officer, and Chair of the Company
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $5.96M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 185,597 shares of Alamar Biosciences, Inc. at $30.33 to $33.11 a share (average $32.14) in 19 transactions, worth $5.96M in total between Oct 27, 2026 and Oct 28, 2026. Shares held after the trade: 1,704,596 (-0.5%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $8.56M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 280,244 shares of Alamar Biosciences, Inc. at $29.35 to $30.85 a share (average $30.56) in 15 transactions, worth $8.56M in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 1,738,314 (-1.4%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $10.3M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 342,527 shares of Alamar Biosciences, Inc. at $29.00 to $30.81 a share (average $29.92) in 23 transactions, worth $10.3M in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 1,789,183 (-0.1%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $5.94M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 216,977 shares of Alamar Biosciences, Inc. at $26.34 to $28.44 a share (average $27.35) in 14 transactions, worth $5.94M in total between Oct 19, 2026 and Oct 20, 2026. Shares held after the trade: 1,851,350 (-0.2%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $4.8M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 173,037 shares of Alamar Biosciences, Inc. at $27.73 a share, worth $4.8M in total on Oct 15, 2026. Shares held after the trade: 1,890,932 (-1.6%).